Canine Cushing's Case Files: The ins and outs of detection and treatment—Case file: Your veterinary team's role in treating and monitoring dogs with hyperadrenocorticism (Sponsored by Dechra Veterinary Products)

Jun 01, 2013
By staff

Veterinary team members are instrumental in communicating with your clients — during visits, on the phone, and through email and social media. Well-trained technicians and other team members can help reinforce veterinarians' messages to clients about signs of illness in pets, the advantages of early disease recognition and treatment, and the importance of follow-up care. Team members should understand hyperadrenocorticism, a common endocrine disease in middle-aged to older dogs, so they are comfortable communicating with clients who have pets that are affected.

The previous Canine Cushing's Case Files article reviewed what team members should know about canine hyperadrenocorticism (HAC, also known as Cushing's syndrome) to help veterinarians identify potential Cushing's patients. It also reviewed the diagnostic procedures that are needed to reach a diagnosis of HAC and the team's role in helping to explain the tests to clients. This article focuses on what team members should know about HAC to help veterinarians successfully treat and monitor dogs with this disease.

Your team supports treatment

Once canine HAC has been diagnosed, team members can reinforce the veterinarian's messages to clients about the importance of treatment. If left untreated, the clinical signs will progress, and HAC increases a dog's risk of developing serious problems such as chronic infections of the urinary tract, skin, and ears; diabetes; thromboembolic events; proteinuria; and hypertension. The treatment goal is to maintain a good quality of life by alleviating clinical signs and secondary medical conditions.

Teach your team about treatment options for canine HAC. VETORYL® CAPSULES (trilostane) are the only FDA-approved treatment for both pituitary-dependent hyperadrenocorticism (PDH) and adrenal-dependent hyperadrenocorticism (ADH) in dogs. The active ingredient in VETORYL Capsules — trilostane — blocks an enzyme in the cortisol production pathway, which decreases cortisol in the body and reduces clinical signs. VETORYL Capsules are clinically effective in treating dogs with PDH and ADH; the drug does not, however, affect tumor growth.

Your team members can also share success stories with clients about other patients with HAC that have been treated at your practice. Clients like to know what to expect from treatment and appreciate hearing about other pets that are being successfully managed.